Lip and oral cavity carcinoma
MONDO:0023644A carcinoma arising in the lip or oral cavity. Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums. Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma. Lip carcinomas are usually basal cell or squamous cell carcinomas.
Also known as: lip and oral cavity cancer, lip and oral cavity carcinoma, oral cancer, oral carcinoma
3093 clinical trials for this condition and its sub-types, 96 tagged with Lip and oral cavity carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Lip and oral cavity carcinoma
-
Oral cavity carcinoma 16 trials · 202 incl. sub-types
9 sub-types
- Oral cavity squamous cell carcinoma 141 trials · 156 incl. sub-types Sub-types →
- Salivary gland carcinoma 26 trials · 36 incl. sub-types Sub-types →
- Oral cavity carcinoma in situ 5 trials Sub-types →
- Tongue carcinoma 4 trials
- Carcinoma of lip 0 trials · 2 incl. sub-types Sub-types →
- Carcinoma of hard palate 1 trial
- Carcinoma of soft palate 1 trial
- Intraoral basal cell carcinoma 0 trials
- Oral cavity mucoepidermoid carcinoma 0 trials Sub-types →
-
Lip and oral cavity squamous cell carcinoma 21 trials · 159 incl. sub-types
1 sub-type
- Oral cavity squamous cell carcinoma 141 trials · 156 incl. sub-types Sub-types →
Most studied deeper sub-types
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Radiation plus immunotherapy: a new hope for advanced head and neck cancer?
Disease control OngoingThis phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could an immunotherapy combo replace harsh chemo for head and neck cancer?
Disease control OngoingThis phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. T…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Vitamin a derivative patch could reverse oral precancer
Disease control OngoingThis trial tests a sticky patch that releases fenretinide, a vitamin A derivative, directly onto precancerous spots inside the mouth. The goal is to see if the patch can shrink these lesions, reduce their severity under the microscope, and lower genetic changes linked to oral can…
Phase 1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy-Chemo cocktail shows promise in head and neck cancer trial
Disease control OngoingThis phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have…
Phase 2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Drug-Radiation combo shows promise for Tough-to-Treat head and neck cancer
Disease control OngoingThis early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Chemo-Immunotherapy cocktail spare head and neck cancer patients from radiation?
Disease control OngoingThis phase 2 trial tests a combination of two chemotherapy drugs (carboplatin and nab-paclitaxel) plus an immunotherapy drug (durvalumab) given before surgery for people with locally advanced head and neck cancer. The goal is to shrink or eliminate the tumor so that radiation—whi…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Immunotherapy may replace chemo in head and neck cancer trial
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or in…
Phase 2 • Sponsor: Loren Mell, MD • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Glow-in-the-Dark mouth scans could catch cancer early
Diagnosis OngoingThis study tests whether special lights and cameras can help find early signs of mouth cancer in people at high risk. About 338 participants with precancerous spots or conditions like Fanconi anemia will have their mouths examined with fluorescence imaging, which makes abnormal c…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
New camera tech could catch mouth cancer earlier
Diagnosis OngoingThis study tests whether special imaging devices can better detect pre-cancerous or cancerous spots in the mouth compared to a standard visual exam. About 63 adults with suspicious mouth lesions or a history of oral cancer will be followed over time. The goal is to see if these a…
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Can a diabetes drug stop oral cancer before it starts?
Prevention OngoingThis study tests whether metformin, a common diabetes drug, can prevent oral cancer in people with precancerous white or red patches in the mouth. About 34 participants will receive either metformin or a placebo for several months. Researchers will check if the patches shrink or …
Phase 2 • Sponsor: University of Arizona • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Could a common diabetes drug stop oral cancer before it starts?
Prevention OngoingThis phase 2 trial tests whether metformin, a widely used diabetes drug, can prevent oral cancer in 26 people with precancerous mouth lesions (leukoplakia or erythroplakia). Participants take metformin by mouth, and researchers check if the lesions shrink or disappear. The goal i…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
New study tests safer pain relief for oral cancer patients
Symptom relief By invitation onlyThis study compares two pain management strategies for adults with oral cancer who have moderate to severe pain. One group receives the opioid tramadol, while the other gets a combination of pregabalin and naproxen sodium. Over 7 days, researchers measure pain reduction, side eff…
Sponsor: Mayo Hospital Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Can a smartphone app help oral cancer patients recover faster?
Symptom relief OngoingThis study tests whether a remote rehabilitation app can improve shoulder and neck recovery in oral cancer patients who had neck dissection surgery. 80 patients are randomly assigned to either standard home exercise materials or the app, which provides daily reminders and lets pa…
Sponsor: Pai Pang • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
New online program aims to empower oral cancer survivors
Symptom relief OngoingThis study tests an online program called Empowered Survivor, designed to help people who have had oral or throat cancer feel more confident managing their health after treatment. Researchers are comparing it to a free online tool already available for cancer survivors. The goal …
Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Can strawberry gummies fight gum disease and oral cancer?
Knowledge-focused OngoingThis early-phase study tests whether strawberry gummies can improve oral health in 36 adults, including smokers and non-smokers. Participants eat two types of gummies (real strawberry or placebo) four times daily for a week. Researchers measure how the body absorbs strawberry com…
Phase 1 • Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC